

CITATION REPORT

List of articles citing

Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study

DOI: 10.1177/0961203396005001081

Lupus, 1996, 5, 31-36.

Source: <https://exaly.com/paper-pdf/26943195/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
113	Pulmonary manifestations of Sjögren's syndrome. 1998 , 19, 687-99, viii		68
112	Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome. 1998 , 56, 345-53		17
111	Sjögren's syndrome: a model for dental care in the 21st century. 1998 , 129, 719-28		23
110	Antiprotozoal drugs. 1998 , 293-305		
109	Treatment of oral dryness related complaints (xerostomia) in Sjögren's syndrome. 1999 , 58, 465-74		38
108	Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. 1999 , 58, 253-6		82
107	Prospects for gene-based immunopharmacology in salivary glands. 2000 , 82, 281-6		10
106	The use of antimalarials in dermatology. 2000 , 11, 185-194		2
105	Questions answered and a \$1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary. 2000 , 136, 1044-9		21
104	Annular erythema of Sjögren's syndrome in a white woman. 2000 , 42, 1069-1073		23
103	Sjögren's syndrome. 2000 , 18, 589-600		23
102	Antimalarials: unapproved uses or indications. 2000 , 18, 17-35		42
101	Use of muscarinic agonists in the treatment of Sjögren's syndrome. 2001 , 101, 249-63		83
100	Outcome measures in Sjögren's syndrome. 2001 , 40, 1085-8		17
99	Antimalarials--the 'real' advance in lupus. <i>Lupus</i> , 2001 , 10, 385-7	2.6	55
98	The oral side of Sjögren syndrome. Diagnosis and treatment. A review. 2002 , 33, 95-106		85
97	Current issues in Sjögren's syndrome. 2002 , 8, 130-40		59

96	Diagnosing, managing, and preventing salivary gland disorders. 2002 , 8, 77-89	88
95	Xerostomia and the geriatric patient. 2002 , 50, 535-43	262
94	Uso de los antimaláricos en dermatología. 2003 , 18, 515-518	2
93	Antibodies against alpha-fodrin in Sjögren's syndrome. 2003 , 2, 109-13	27
92	Clinical manifestations and early diagnosis of Sjögren syndrome. 2004 , 164, 1275-84	445
91	Sjögren's syndrome. 2004 , 18, 313-29	30
90	Primary Sjögren's syndrome: new clinical and therapeutic concepts. 2005 , 64, 347-54	183
89	Sjögren's syndrome. 2004 , 18, 313-329	42
88	An update of the etiology and management of xerostomia. 2004 , 97, 28-46	227
87	Sjogren's Syndrome. 2005 , 261-289	1
86	Antimalarials. 2005 , 347-372	
85	Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. 2005 , 64, 1050-5	59
84	Autoimmune Diseases of the Skin. 2005 ,	4
83	Lamivudine is not effective in primary Sjögren's syndrome. 2005 , 64, 1326-30	8
82	Sjögren's syndrome. 2005 , 366, 321-31	1061
81	[Synthetic antimalarials]. 2005 , 132, 665-74	5
80	Cutaneous Lupus Erythematosus. 2005 ,	11
79	Optimal use of antimalarials in treating cutaneous lupus erythematosus. 2005 , 6, 1-11	29

78	[Antimalarials in systemic diseases]. 2005 , 205, 230-2	6
77	[Sjögren syndrome. New therapeutic approaches]. 2005 , 124, 111-5	3
76	[Antimalarials: an update in rheumatic diseases]. 2006 , 2, 190-201	8
75	Sjögren's syndrome in dermatology. 2006 , 24, 393-413	51
74	Management of patients presenting with Sjogren's syndrome. 2006 , 20, 791-807	30
73	Therapy of cutaneous lupus erythematosus. 2006 , 1, 105-120	2
72	New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. 2007 , 38, 1858-63	49
71	Syndrome de Gougerot-Sjögren: critères de classification, lymphomes, traitements. 2007 , 74, 737-744	0
70	Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?. 2007 , 26, 1248-53	25
69	Primary Sjogren's syndrome: current and prospective therapies. 2008 , 37, 273-92	58
68	Sjögren's syndrome: diagnosis and therapeutic challenges in the elderly. 2008 , 25, 19-33	13
67	Patient-reported outcomes including fatigue in primary Sjögren's syndrome. 2008 , 34, 949-62, ix	19
66	Treatment of primary Sjögren syndrome: a systematic review. 2010 , 304, 452-60	240
65	Primary Sjogren's syndrome: too dry and too tired. 2010 , 49, 844-53	88
64	Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients. 2010 , 49, 1164-72	63
63	Autoimmune Diseases of the Skin. 2011 ,	4
62	Implications of long-term medication of oral steroids and antimalarial drugs in primary Sjögren's syndrome. 2011 , 11, 2125-9	5
61	Treatment of Sjögren's syndrome-associated dry eye an evidence-based review. 2011 , 118, 1242-52	52

60	Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome. 2011 , 31, 1045-9	48
59	Sjögren's Syndrome. 2011 , 283-324	1
58	Geriatric Rheumatology. 2011 ,	6
57	A review on recent advances in dry eye: Pathogenesis and management. 2011 , 4, 50-6	35
56	Recurrent parotitis as a presentation of primary pediatric Sjögren syndrome. 2012 , 129, e179-82	32
55	Sjögren's Syndrome. 2012 ,	7
54	Topical and systemic medications for the treatment of primary Sjögren's syndrome. 2012 , 8, 399-411	123
53	Biologic treatments in Sjögren's syndrome. 2012 , 41, e495-509	12
52	Rheumatologie aus der Praxis. 2012 ,	1
51	[Liposomal local therapy as treatment for sicca symptoms in patients with primary Sjögren's syndrome]. 2013 , 61, 921-7	14
50	Oral dryness in Sjögren's syndrome patients. Not just a question of water. 2013 , 12, 567-74	55
49	Extraskelletal Manifestations in Rheumatoid Arthritis - Clinical Cases. 2013 ,	
48	Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. 2014 , 312, 249-58	176
47	Outcome measures for primary Sjögren's syndrome: a comprehensive review. 2014 , 51, 51-6	55
46	Pulmonary Manifestations of Rheumatic Disease. 2014 ,	2
45	Sjögren syndrome. 2014 , 186, E579-86	101
44	Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. 2015 , 74, 526-31	185
43	Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study. 2016 , 31, 1127-35	35

42	Treatment of primary Sjögren syndrome. 2016 , 12, 456-71	102
41	Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis. 2017 , 18, 186	44
40	Diagnosis and treatment of primary Sjogren's syndrome: an update. 2017 , 17, 6-11	
39	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. 2017 , 958-982.e7	2
38	Sialendoscopic management of autoimmune sialadenitis: a review of literature. 2017 , 37, 148-154	12
37	Ocular Involvement in Sjögren's Syndrome: Advances in Therapy. 2018 , 4, 99-109	4
36	Hydroxychloroquine affects bone resorption both in vitro and in vivo. 2018 , 233, 1424-1433	17
35	Cutaneous features and diagnosis of primary Sjögren syndrome: An update and review. 2018 , 79, 736-745	15
34	Application of LIPUS to Salivary Glands. 2018 , 55-62	
33	Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults. 2018 , 44, 419-436	23
32	[Sjögren's syndrome update: Clinical and therapeutic aspects]. 2019 , 40, 433-439	6
31	Sjogren's Syndrome. 2019 , 559-567	
30	Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma. 2019 ,	25
29	Innate immunity and interferons in the pathogenesis of Sjögren's syndrome. 2019 ,	26
28	How to treat Sjögren's syndrome. 2019 ,	5
27	Sjögren's Syndrome as an Ocular Problem: Signs and Symptoms, Diagnosis, Treatment. 2019 ,	1
26	Management of Sjögren's. 2019 , 745-758	1
25	Viral antigens elicit augmented immune responses in primary Sjögren's syndrome. 2020 , 59, 1651-1661	10

24	[Longstanding Sjögren's syndrome without heightened risk of lymphoma]. 2020 , 79, 571-573		
23	Clinical practice guidance for Sjögren's syndrome in pediatric patients (2018) - summarized and updated. 2021 , 31, 283-293		2
22	Pharmacological Management of Sjögren's Syndrome. 2021 , 197-215		0
21	In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV. 2021 , 10, 22		3
20	Analytical Methodologies for Determination of Hydroxychloroquine and Its Metabolites in Pharmaceutical, Biological and Environmental Samples. 2021 , 17,		0
19	Current and future therapies for primary Sjögren syndrome. 2021 , 17, 475-486		10
18	Efficacy of hydroxychloroquine for treating annular erythema associated with Sjögren's syndrome. 2021 , 48, 1526-1532		0
17	Association between increased Bcl-2, Fas and FasL levels and inflammation extent in labial salivary glands during primary Sjögren's syndrome. 2021 ,		0
16	The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis. 2021 , 12, 693796		0
15	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. 2013 , 917-940.e6		2
14	Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren's syndrome. 2019 , 8,		9
13	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. <i>EMBO Molecular Medicine</i> , 2020 , 12, e12476	12	29
12	Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis/polymyositis. <i>Clinics</i> , 2013 , 68, 621-7	2.3	8
11	Sjögren's syndrome: pathogenesis, diagnosis, and treatment. <i>Nurse Practitioner</i> , 2001 , 26, 50, 53-8	0.4	1
10	Pharmakotherapie. 2007 , 129-174		
9	Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. 2009 , 883-907		0
8	Kollagenosen. 2012 , 103-131		
7	Pharmakotherapie. 2014 , 121-168		

- 6 MANAGEMENT OF DRY MOUTH. *Dental Clinics of North America*, **1997**, 41, 863-875 3.3 27
- 5 Composition and regulation of the immune microenvironment of salivary gland in Sjögren's syndrome. 13, 0
- 4 Lokal og systemisk behandling av munntørhet. **2013**, 123, 0
- 3 Risk of dementia or Parkinson's disease in the presence of Sjögren's syndrome: A systematic review and meta-analysis. 16, 0
- 2 The Future of Targeted Treatment of Primary Sjögren's Syndrome: A Focus on Extra-Glandular Pathology. **2022**, 23, 14135 0
- 1 Salivary gland LAMP3 mRNA expression is a possible predictive marker in the response to hydroxychloroquine in Sjögren's disease. **2023**, 18, e0282227 0